Breaking Down SG&A Expenses: Pfizer Inc. vs Lantheus Holdings, Inc.

A Tale of Two Giants: Pfizer Inc. vs. Lantheus Holdings, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Over the past decade, Pfizer Inc. and Lantheus Holdings, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. While Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, Lantheus has experienced a dramatic rise, with expenses growing by over 270% from 2014 to 2023. This surge reflects Lantheus's aggressive expansion and strategic investments. In 2023, Lantheus's SG&A expenses reached nearly 2% of Pfizer's, highlighting the scale difference but also the rapid growth of Lantheus. As the pharmaceutical industry continues to innovate, these financial insights provide a window into the strategic priorities and market positioning of these two influential companies.